Associated factors for potential clinically significant drug-drug interactions in adult intensive care
DOI:
https://doi.org/10.11606/issn.2176-7262.v53i4p379-388Keywords:
Drug Interactions, Adverse Events, Intensive Care Units, Critical Care, Patient SafetyAbstract
Study Design: Cross-sectional. Objective: characterizing major and contraindicated potential drug-drug interactions (PDDI) in adult intensive care as well as determining their prevalence, risk factors, and potentially high-risk medications. Methods: The sample was composed of 309 patients hospitalized in an adult intensive care unit in the Midwest Region of Minas Gerais state, Brazil. Clinical data and drug profile were prospectively collected. The PDDI were characterized using the Micromedex 2.0 as to severity, prevalence, and clinical implications. Descriptive analyses were performed for qualitative and continuous variables. Generalized Linear Models with Gamma and Poisson distribution were used to assess the relationship between a set of independent variables and the prevalence of major and contraindicated PDDI (p<0.05). Results: A total of 81.8% (n = 251) were exposed to, at least, a major or contraindicated PDDI. More than a third (37.4%) of these participants were exposed to six or more IMp. Drugs with action on the nervous system contributed to a greater probability of major and/or contraindicated PDDI. Elderly (p = 0.006), male (p = 0.028), and polymedicated (<0.001) people were more likely to be exposed to at least a higher or contraindicated PDDI. Conclusion: Potentially major and contraindicated drug interactions showed high frequency. Elderly, male, and polymedicated people were more exposed to larger and/or contraindicated PDDI. It is important that health professionals are aware of the risks and potential adverse events related to major and contraindicated PDDI so that measures might be implemented to promote patient safety.
Downloads
References
Uijtendaal E, Van Harssel LLM, Hugenholtz GWK, Kuck EM, Zwart-Van Rijkom JEF, Cremer OL, et al. Analysis of potential drug-drug interactions in medical intensive care unit patients. Pharmacotherapy. 2014;34(3):213–9.
Hennessy S, Leonard C, Gagne JJ, Flory JH, Han X, Brensinger CM, et al. Pharmacoepidemiologic Methods for Studying the Health Effects of Drug-Drug Interactions. Clin Pharmacol Ther. 2016;99(1):92–100.
Guthrie B, Makubate B, Hernandez-Santiago V, Dreishculte T. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995-2010. BMC Med. 2015;13:74.
Askari M, Eslami S, Louws M, Wierenga PC, Dongelmans DA, Kuiper RA, et al. Frequency and nature of drug-drug interactions in the intensive care unit. Pharmacoepidemiol Drug Saf. 2013;22(4):430–7.
Secoli SR, Figueras A, Lebrao ML, de Lima FD, Santos JLF. Risk of potential drug-drug interactions among Brazilian elderly: a population-based, cross-sectional study. Drugs Aging. 2010;27(9):759–70.
Fitzmaurice MG, Wong A, Akerberg H, Avramovska S, Smithburger PL, Buckley MS, et al. Evaluation of Potential Drug–Drug Interactions in Adults in the Intensive Care Unit: A Systematic Review and Meta-Analysis. Drug Saf. 2019;42(9):1035–44.
Cortes ALB, Silvino ZR, Santos FBM, Pereira JAC, Tavares GS. Drug Interactions Prevalence Involving High-Surveillance Drugs: a Cross-Sectional Study. Rev Min Enferm. 2019;23:e-1226.
Reis AMM, Cassiani SH de B. Prevalence of potential drug interactions in patients in an intensive care unit of a university hospital in Brazil. Clinics. 2011;66(1):9–15.
Carvalho REFL, Reis AMM, Faria LMP, Azevedo Zago KS, Cassiani SHB. Prevalence of drug interactions in intensive care units in Brazil. Acta Paul Enferm. 2013;26(2):150–7.
Pessoa T de L, Clemente Junior WS, Costa TX da, Bezerra PK do V, Martins RR. Drug interactions in maternal intensive care: prevalence, risk factors, and potential risk medications. Einstein (Sao Paulo). 2019;17(3):1–7.
Janković SM, Pejčić A V., Milosavljević MN, Opančina VD, Pešić N V., Nedeljković TT, et al. Risk factors for potential drug-drug interactions in intensive care unit patients. J Crit Care. 2018;43:1–6.
Rodrigues AT, Stahlschmidt R, Granja S, Pilger D, Falcão ALE, Mazzola PG. Prevalence of potential drug-drug interactions in the intensive care unit of a Brazilian teaching hospital. Brazilian J Pharm Sci. 2017;53(1):e16109.
Iyer S, Wagh BR, Godbole DD, Deshmukh SS, Deshpande PR. Identification and Assessment of Potential Drug–Drug Interactions in Intensive Care Unit Patients. Indian J Crit Care Med. 2019;23(4):170–4.
Rodrigues AT, Stahlschmidt R, Granja S, Falcão ALE, Moriel P, Mazzola PG. Clinical relevancy and risks of potential drug-drug interactions in intensive therapy. Saudi Pharm J. 2015;23(4):366–70.
Łój P, Olender A, Ślęzak W, Krzych ŁJ. Pharmacokinetic drug-drug interactions in the intensive care unit — single-centre experience and literature review. Anaesthesiol Intensive Ther. 2017;49(4):259–67.
Shakeel F, Khan JA, Aamir M. Relationship of factors affecting clinically important drug interactions and their significance in surgical intensive care units in Pakistan. Lat Am J Pharm. 2018;37(4):643–50.
von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. Int J Surg. 2014;12(12):1495–9.
Micromedex® Healthcare Series. Greenwood Village (US): Thomson Reuters (Healthcare) [Internet]. [cited 2019 Nov 5]. Available from: https://www-micromedexsolutions-com.ez32.periodicos.capes.gov.br
World Health Organization. Collaborating Center for Drug Statistics Methodology. ATC/DDD Index 2019 [Internet]. [cited 2019 Jan 24]. Available from: https://www.whocc.no/atc_ddd_index/
Farzanegan B, Alehashem M, Bastani M, Baniasadi S. Potential drug-drug interactions in cardiothoracic intensive care unit of a pulmonary teaching hospital. J Clin Pharmacol. 2015;55(2):132–6.
Farrokh S, Tahsili-Fahadan P, Ritzl EK, Lewin JJ, Mirski MA. Antiepileptic drugs in critically ill patients. Crit Care. 2018;22(1):153.
Wang H, Wang C, Wang Y, Tong H, Feng Y, Li M, et al. Sedative drugs used for mechanically ventilated patients in intensive care units: a systematic review and network meta-analysis. Curr Med Res Opin. 2019;35(3):435–46.
Panahi Y, Dehcheshmeh HS, Mojtahedzadeh M, Joneidi-Jafari N, Johnston TP, Sahebkar A. Analgesic and sedative agents used in the intensive care unit: A review. J Cell Biochem. 2018;119(11):8684–93.
Instituto para Práticas Seguras no Uso de Medicamentos. Medicamentos potencialmente perigosos de uso hospitalar - lista atualizada 2019. Vol. 8, Boletim ISMP Brasil. 2019. p. 1–9.
Reis MAS, Gabriel CS, Zanetti ACB, Bernardes A, Laus AM, Pereira LRL. Potentially hazardous drugs: Identification of risks and error prevention barriers in intensive care. Texto e Context Enferm. 2018;27(2):e5710016.
Reichheld AM, Hills-Evans K, Sheehan JK, Tocci NX, Tandon M, Hsu D, et al. A national survey of approaches to manage the ICU patient with opioid use disorder. J Crit Care. 2019;54:42–7.
Andrade S, Bartels DB, Lange R, Sandford L, Gurwitz J. Safety of metamizole: a systematic review of the literature. J Clin Pharm Ther. 2016;41(5):459–77.
Kötter T, Da Costa BR, Fässler M, Blozik E, Linde K, Jüni P, et al. Metamizole-associated adverse events: A systematic review and meta-analysis. PLoS One. 2015;10(4):e0122918.
Scrignoli CP, Teixeira VCMC, Leal DCP. Drug interactions among the most prescribed drugs in adult intensive care unit. Brazilian J Hosp Pharm Heal Serv. 2016;7(2):26–30.
Currow DC, Vella-Brincat J, Fazekas B, Clark K, Doogue M, Rowett D. Pharmacovigilance in hospice/palliative care: Rapid report of net clinical effect of metoclopramide. J Palliat Med. 2012;15(10):1071–5.
Simpson PM, Bendall JC, Middleton PM. Review article: Prophylactic metoclopramide for patients receiving intravenous morphine in the emergency setting: A systematic review and meta-analysis of randomized controlled trials. Emerg Med Australas. 2011;23(4):452–7.
Marquet K, Claes N, De Troy E, Kox G, Droogmans M, Vleugels A. A multicenter record review of in-hospital adverse drug events requiring a higher level of care. Acta Clin Belgica Int J Clin Lab Med. 2017;72(3):156–62.
Phansalkar S, Desai A, Choksi A, Yoshida E, Doole J, Czochanski M, et al. Criteria for assessing high-priority drug-drug interactions for clinical decision support in electronic health records. BMC Med Inform Decis Mak. 2013;13:65.
Paterno MD, Maviglia SM, Gorman PN, Seger DL, Yoshida E, Seger AC, et al. Tiering Drug-Drug Interaction Alerts by Severity Increases Compliance Rates. J Am Med Informatics Assoc. 2009;16:40–6.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 Juliano Teixeira Moraes, Juliana Moreira Maia, Olívia Maria Trindade, Luiz Alberto Oliveira, Cristina Sanches, Danilo Donizetti Trevisan
This work is licensed under a Creative Commons Attribution 4.0 International License.
